Background: Preventing steroid resistance and maintaining disease control are significant challenges to overcome in treating SLE patients [1] . P-glycoprotein (P-gp) of membrane transporters, a product of the multiple drug resistance (MDR)-1 gene, is known to play a pivotal role in the acquisition of drug resistance to chemotherapy in autoimmune diseases [2] .Inhibition of P-gp could overcome such drug resistance [3,4] . So we observed the effect of P-gp monoclonal antibody on MRL/lpr lupus mice. Objectives: To investigate the efficacy of P-glycoprotein monoclonal antibody in the treatment of the MRL/lpr mice. Methods: Twenty four 14-week-old MRL/lpr female mice were divided into 3groups:group 1 (G1)were treated with P-glycoprotein monoclonal through caudal vein, group 2 (G2)were treated with P-glycoprotein monoclonal three times and group 0 (G0)were treated with 0.5ml normal saline as controls. Twenty-four hours proteinuria and body weight were assessed every two weeks.Enzyme linked immunosorbent assay (ELISA)was used to measure the levels of serum anti-dsDNA antibodies. The histopathology changes of the kidneys were observed. Results: From the 22th week,the body weight of groups Gl and G2 increased significantly than that of the group G0 (p<0.05). At the 22th weeks,the 24 hours proteinuria in group Gl (1.9±1.1)mg and G2 (1.4±0.9)mg was decreased than that in group G0 (3.1+1.9)mg (p<0.05), and at the 26th weeks,that of groups G1 (2.4±1.4)mg and G2 (1.8±1.1)mg was also significantly decreased than in group G0 (5.3±2.2)mg (p<0.01). At week 26,serum creatinine decreased significantly in both groups G1 (7.0±2.9)umol/L and G2 (6.1±2.5)umol/L than in group G0 (12.7±1.3)umol/L (p<0.05). One week after treatment, the levels of anti-dsDNA antibodies in group Gl (43±19)x10 2 U/ml and G2 (45±32)x10 2 U/ml were both significantly decreased than those of the group G0 (87±39)x10 2 U/ml (p<0.05),and at the 26th weeks the difference between group G2 (35±11)xl0
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M. Wang, P. Zeng, G. Zhou, J. Lv, Q. Wang. Department of Rheumatology and Immunology, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, CHINA., Shenzhen, China Background: Preventing steroid resistance and maintaining disease control are significant challenges to overcome in treating SLE patients [1] . P-glycoprotein (P-gp) of membrane transporters, a product of the multiple drug resistance (MDR)-1 gene, is known to play a pivotal role in the acquisition of drug resistance to chemotherapy in autoimmune diseases [2] .Inhibition of P-gp could overcome such drug resistance [3, 4] . So we observed the effect of P-gp monoclonal antibody on MRL/lpr lupus mice. Objectives: To investigate the efficacy of P-glycoprotein monoclonal antibody in the treatment of the MRL/lpr mice. Methods: Twenty four 14-week-old MRL/lpr female mice were divided into 3groups:group 1 (G1)were treated with P-glycoprotein monoclonal through caudal vein, group 2 (G2)were treated with P-glycoprotein monoclonal three times and group 0 (G0)were treated with 0.5ml normal saline as controls. Twenty-four hours proteinuria and body weight were assessed every two weeks.Enzyme linked immunosorbent assay (ELISA)was used to measure the levels of serum anti-dsDNA antibodies. The histopathology changes of the kidneys were observed. Results: From the 22th week,the body weight of groups Gl and G2 increased significantly than that of the group G0 (p<0.05). At the 22th weeks,the 24 hours proteinuria in group Gl (1.9±1.1)mg and G2 (1.4±0.9)mg was decreased than that in group G0 (3.1+1.9)mg (p<0.05), and at the 26th weeks,that of groups G1 (2.4±1.4)mg and G2 (1.8±1.1)mg was also significantly decreased than in group G0 (5.3±2.2)mg (p<0.01). At week 26,serum creatinine decreased significantly in both groups G1 (7.0±2.9)umol/L and G2 (6.1±2.5)umol/L than in group G0 (12.7±1.3)umol/L (p<0.05). One week after treatment, the levels of anti-dsDNA antibodies in group Gl (43±19)x10 2 U/ml and G2 (45±32)x10 2 U/ml were both significantly decreased than those of the group G0 (87±39)x10 2 U/ml (p<0.05),and at the 26th weeks the difference between group G2 (35±11)xl0 2 U/ml and G0 (59±35)x10 2 U/ml was statistically significant. The nephron crescent formation in group G1 (0.11±0.05)and G2 (0.09±0.01)was significandy lower that Background: Neuropsychiatric Systemic Lupus Erythematosus (NPSLE) is a severe complication of SLE, including a variety of neurological and psychiatric features. Previous studies have demonstrated the close relationship between NPSLE and inflammation. HMGB1-TLR4 signaling pathway is the up-stream pathway of NF-κB, which could upregulate the expression of various cytokines and other inflammatory mediators. Objectives: The objective of the study was to explore the potential mechanism of HMGB1-TLR4 axis in SLE. Methods: The study population consisted of 107 SLE patients and 43 ageand sex-matched healthy controls. 73 SLE patients had active disease. 36 of these had NPSLE. The serum anti-NR2A antibodies levels were measured by ELISA. Clinical and serological parameters were assessed according to routine procedures. HMGB1 and TLR4 levels were measured by ELISA.Statistical analyses were performed by using the chi-square test and the t-test. Results: CNS manifestations accounted for 94% (34/36 patients), while involvement of the PNS was 6% (2/36patients). The majority of the manifestations were Seizure disorders (n=17; 47.2%),Headache (n=12; 33.3%), Cognitive dysfunction (n=10; 27.8%), Psychoses (n=8; 22.2%).Within the group of active patients those with NP manifestations had higher HMGB1 levels (0.451 (0.292 to 0.583)) compared to active patients with non-NP manifestations (0.356 (0.098 to 0.436)). In patients with NP (0.429 (0.313 to 0.526)) and non-NP (0.375 (0.196 to 0.478)) manifestations during active periods of the disease, TLR4 levels significant increased in comparison to the controls. TLR4 levels were significantly higher in active patients (0.401 (0.196 to 0.526)) compared to quiescent patients. There was a significant positive correlation between levels of HMGB1 and TLR4 in the total patients group (P<0.0001, r=0.939).We observed a correlation between HMGB1 levels and SLEDAI (P<0.0001, r=0.804). Also, TLR4 levels showed a significant correlation with SLEDAI (P<0.0001, r=0.809). HMGB1 levels correlated with anti-dsDNA levels (P<0.0001, r=0.558). Similarly, TLR4 showed a correlation with anti-dsDNA levels (P<0.0001, r=0.522).We observed a negative correlation in the total SLE group between C3, C4 and HMGB1 levels (P<0.0001, r=-0.545 and P<0.0001, r=-0.270 respective. Also, TLR4 showed a significant negative correlation with C3 and C4 (P<0.0001, r=-0.559 and P<0.0001, r=-0.285 respectively). Conclusions: Our data suggest that HMGB1-TLR4 axis plays an important role in the pathogenesis of SLE as well as NPSLE.
